Valuation: SCYNEXIS, Inc.

Market Cap 4.43Cr 3.89Cr 3.67Cr 3.34Cr 6.26Cr 424.36Cr 6.3Cr 44Cr 17Cr 216.8Cr 17Cr 16Cr 696.76Cr P/E 2026 *
-1.53x
P/E 2027 * -1.92x
Enterprise Value 4.43Cr 3.89Cr 3.67Cr 3.34Cr 6.26Cr 424.36Cr 6.3Cr 44Cr 17Cr 216.8Cr 17Cr 16Cr 696.76Cr EV / Sales 2026 *
71.5x
EV / Sales 2027 * 6.63x
Free-Float
98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day-1.35%
1 week-1.57%
Current month-16.06%
1 month-15.41%
3 months+15.22%
6 months-37.70%
Current year-13.23%
1 week 4.27
Extreme 4.27
5
1 month 4.08
Extreme 4.08
6.09
Current year 3.53
Extreme 3.53
9.12
1 year 3.53
Extreme 3.53
9.12
3 years 3.53
Extreme 3.53
24.56
5 years 3.53
Extreme 3.53
64.8
10 years 3.53
Extreme 3.53
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 50 09/09/2026
Chief Tech/Sci/R&D Officer - 14/09/2026
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Free

Director

11,500 0.1156%
09/09/26 Free

Chief Financial Officer

1,00,000 1.0051%
01/04/26 Buy

Chief Executive Officer

2,17,390 0.2736%
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%-1.57%-49.19%-74.83% 4.43Cr
+0.13%+2.65%+65.61%+114.28% 1,05300Cr
+0.20%+0.46%+52.60%+69.24% 65TCr
-0.29%+0.14%+20.96%+70.93% 47TCr
-0.85%-0.25%+38.63%+44.47% 35TCr
+0.71%+3.26%+22.46%+30.30% 27TCr
+1.23%+1.00%+11.97%+13.63% 25TCr
+2.11%+7.51%+52.89%+55.37% 22TCr
+0.83%+0.55%+35.99%+101.70% 19TCr
0.00%-9.43%-31.91%-60.56% 17TCr
Average +0.21%+0.27%+22.00%+36.45% 36.27TCr
Weighted average by Cap. +0.22%+1.00%+41.03%+68.05%

Financials

2026 *2027 *
Net sales 6L 5L 5L 5L 9L 5.94Cr 9L 61.44L 23.8L 3.03Cr 23.26L 22.76L 9.75Cr 66.77L 58.59L 55.34L 50.43L 94.4L 64Cr 95.08L 6.62Cr 2.56Cr 33Cr 2.51Cr 2.45Cr 105.08Cr
Net income -3.06Cr -2.68Cr -2.53Cr -2.31Cr -4.32Cr -292.8Cr -4.35Cr -30Cr -12Cr -149.59Cr -11Cr -11Cr -480.76Cr -3.24Cr -2.85Cr -2.69Cr -2.45Cr -4.58Cr -310.82Cr -4.62Cr -32Cr -12Cr -158.79Cr -12Cr -12Cr -510.34Cr
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
26/26/26 $4.390 -1.35% 31,615
24/26/24 $4.450 -3.99% 38,016
23/26/23 $4.635 -4.63% 65,733
22/26/22 $4.860 +10.45% 1,67,832
21/26/21 $4.400 -1.35% 45,907
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.450USD
Average target price
36.55USD
Spread / Average Target
+721.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock